Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial LANCET Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., Fogliatto, L., Herishanu, Y., Banerji, V., Coutre, S., Follows, G., Walker, P., Karlsson, K., Ghia, P., Janssens, A., Cymbalista, F., Woyach, J. A., Salles, G., Wierda, W. G., Izumi, R., Munugalavadla, V., Patel, P., Wang, M., Wong, S., Byrd, J. C. 2020; 395 (10232): 1278–91

View details for Web of Science ID 000526818800027